Warfarin-Fluconazole II - A metabolically based drug interaction: In vivo studies

Drug Metabolism and Disposition

Volumn 24, Issue 4, 1996, Pages 422-428

  Black, Douglas J ^a   Kunze, Kent L ^a   Wienkers, Larry C ^a   Gidal, Barry E ^a   Seaton, Terry L ^a   McDonnell, Neil D ^a   Evans, Jennifer S ^a   Bauwens, J Eric ^a   Trager, William F ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FLUCONAZOLE; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; CATALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG INHIBITION; HUMAN; HUMAN EXPERIMENT; HYPOPROTHROMBINEMIA; MALE; METABOLIC CLEARANCE RATE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTHROMBIN TIME;

ADULT; ANTICOAGULANTS; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FLUCONAZOLE; HALF-LIFE; HUMANS; MALE; PROTHROMBIN TIME; STEREOISOMERISM; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; WARFARIN;

EID: 0029996292     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. D. S. Hewick and J. McEwen: Plasma half-lives, plasma metabolites and the anticoagulant efficacies of the enantiomers of warfarin in man. J. Pharm. Pharmacol. 25, 458-465 (1973).
2. A. Breckenridge, M. Orme, H. Wessling, R. J. Lewis, and R. Gibbons: Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin. Pharmacol. Ther. 15, 424-430 (1974).
3. R. A. O'Reilly: Studies of the optical enantiomorphs of warfarin in man. Clin. Pharmacol. Ther. 16, 348-354 (1974).
4. A. E. Rettie, K. R. Korzekwa, K. L. Kunze, R. F. Lawrence, A. C. Eddy, T. Aoyama, H. V. Gelboin, F. J. Gonzalez, and W. F. Tragen Hydroxylation of warfarin by human cDNA expressed cytochrome P450: a role for P4502C9 in the etiology of (S)-warfarin drug interactions. Chem. Res. Toxicol. 5, 54-59 (1992).
5. S. Toon, L. K. Low, M. Gibaldi, W. F. Trager, R. A. O'Reilly, C. H. Motley, and D. A. Goulart: The warfarin sulfinpyrazone interaction: stereochemical considerations. Clin. Pharmacol. Ther. 39, 15-24 (1986).
6. L. D. Heimark, L. C. Wienkers, K. L. Kunze, M. Gibaldi, A. C. Eddy, W. F. Trager, R. A. O'Reilly, and D. A. Goulart: The mechanism of the interaction between amiodarone and warfarin in humans. Clin. Pharmacol. Ther. 51, 398-407 (1992).
7. R. A. O'Reilly, D. A. Goulart, K. L. Kunze, J. Neal, M. Gibaldi, A. C. Eddy, and W. F. Trager: Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin. Pharmacol Ther. 51, 656-667 (1992).
8. K. L. Kunze, L. C. Wienkers, K. E. Thummel, and W. F. Trager: Warfarin-fluconazole I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab. Dispos. 24, 414-421 (1996).
9. J. D. Lazar and D. M. Hiligoss: The clinical pharmacology of fluconazole. Semin. Oncol. 17, 14-18 (1990).
10. L. D. Heimark, S. Toon, D C. Swinney, and W. F. Trager: The synthesis of deuterium labelled metabolites of warfarin and phenprocoumon. J. Labelled Campd. Radiopharm. 23, 137-148 (1985).
11. R. A. O'Reilly and P.M. Aggeler: Studies on coumarin anticoagulant drugs: initiation of warfarin therapy without a loading dose. Circulation 38, 169-177 (1968).
12. R. F. Lawrence, A. E. Rettie, A. C. Eddy, and W. F. Trager: Chemical synthesis, absolute configuration, and stereochemistry of 10-hydroxywarfarin: a major oxidative metabolite of (+)-(R)-warfarin from hepatic microsomal preparations. Chirality 2, 96-105 (1990).
13. R. A. O'Reilly, E. Nelson, and G. Levy: Physiochemical and physiological factors affecting the absorption of warfarin in man. J. Pharm. Sci. 55, 435-437 (1966).
14. S. Diamond: In "Information and Error: An Introduction to Statistical Analysis," p. 104. Basic Books. New York, 1959.
15. A. E. Rettie, A. C. Eddy, L. D. Heimark, M. Gibaldi, and W. F. Tragen Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab. Dispos. 17, 265-270 (1989).
16. S. D. Hall, M. A. Hamman, A. E. Rettie, L. C. Wienkers, W. F. Trager, M. Vandenbranden, and S. A. Wrighton: Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab. Dispos. 22, 975-978 (1994).
17. L. L. Crussell-Porter, J. P. Rindone, M. A. Ford, and D. W. Jaskan Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch. Intern. Med. 153, 102-104 (1993).
18. D. R. Abernethy, L. S. Kaminsky, and T. H. Dickinson: Selective inhibition of warfarin metabolism by diltiazem in humans. J. Pharmacol. Exp. Ther. 257, 411-415 (1991).
19. S. Toon, K. J. Hopkins, F. M. Garstang, and L. Aarons: Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin. Pharmacol. Ther. 42, 33-41 (1987).
20. L. S. Kaminsky, S. M. de Morais, M. B. Faletto, D. A. Dunbar, and J. A. Goldstein: Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol. Pharmacol. 43, 234-239 (1993).
21. M. He, K. L. Kunze, and W. F. Tragen Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. Drug Metab. Dispos. 23, 659-663 (1995).